[Persistent CK-elevation after CSE inhibitor therapy].
Faehling
M
M
Leschke
M
M
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control*; D003402:Creatine Kinase / Q000097:blood*; D052279:Creatine Kinase, MB Form; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017202:Myocardial Ischemia / Q000097:blood
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form